Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a recent paper by Yuankai Shi, Professor of Oncology and Chief Physician at Cancer Hospital Chinese Academy of Medical Sciences, published in Nature Medicine:
“Glecirasib in KRASG12C-mutated non-small cell lung cancer: a phase 2b trial.
119 Chinese patients
Prior ICI used:94%
- ORR=47.9%
- PFS=8.2 months
- OS=13.6 months
G3-5 Adverse Effects – 60.5% (TRAE:38.7%, no G5).”
“Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial”
Authors: Yuankai Shi, Jian Fang, Ligang Xing, Qiao Li, Zhiyue Rao et al.
More posts featuring Yakup Ergün.
